Evaluasi Penggunaan Antibiotik pada Pasien Covid-19 di RSUP Prof. Dr. R. D. Kandou Manado Periode Januari-Maret 2021

Authors

  • Christian Aseng
  • Weny Wiyono
  • Meilani Jayanti

DOI:

https://doi.org/10.35799/pha.12.2023.42200

Keywords:

Covid-19, Antibiotik, ATC/DDD, DU 90%

Abstract

Covid-19 adalah penyakit infeksi jenis baru yang disebabkan oleh virus Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2). Penelitian ini bertujuan untuk mengetahui profil penggunaan dan kuantitas penggunaan antibiotik yang diberikan pada pasien Covid-19 di RSUP Prof. Dr. R. D. Kandou Manado periode Januari-Maret 2021. Didapatkan sebanyak 60 sampel rekam medis, kemudian dianalisis secara kuantitatif menggunakan metode ATC/DDD. Didapat 7 jenis antibiotik yang diberikan pada pasien Covid-19 yaitu  Azitromisin (51,72%), Seftriakson (22,99%), Levofloksasin (17,24%), Sefadroksil (2,30%), Meropenem (2,30%), Moksifloksasin (2,30%) dan Siprofloksasin (1,15%). Diperoleh nilai total DDD/100 pasien-hari sebesar 97,36 DDD/100 pasien-hari, antibiotik Azitromisin memiliki nilai DDD/100 hari-pasien tertinggi sebesar 44,54 DDD/100 pasien-hari, dan antibiotik yang masuk dalam segmen 90% adalah Azitromisin (45,75%), Seftriakson (29,85%) dan Levofloksasin (16,02%).

References

Biswas M, S. Rahaman, T.K Biswas, Z. Haque dan B. Ibrahim. 2020. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patiens: A Symtematic Review and MetaAnalysis. Intervirology. 64 : 36- 47.

Del Rio, C., Collins, L. F., dan Malani, P. 2020. Long-term Health Consequences of COVID-19. JAMA - Journal of the American Medical Association. 324(17) :1723–1724.

Langford, B.J., So, M., Raybardhan, S., Leung, V., Soucy, J.R., Westwood, D., Daneman, N., MacFadden, D.R. 2021. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect; 27(4): 520-531.

Langford, B.J., So, M., Raybardhan, S., Leung, V., Westwood, D., MacFadden, D.R. 2020. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect; 26:1622.

Lavan, A.H., dan P. Gallagher. 2016. Predicting Risk of Adverse drug Reactions in Older Adults. Ther Adv Drug Saf;. 7(1):11-22.

Leng, J., dan D.R. Goldstein. 2010. Impact of Aging on Viral Infection. Microbes Infect;. 12(14-15): 1120-4.

Mahmudah, F., Sumiwi S., dan Hartini S. 2016. Studi Penggunaan Antibiotik Berdasarkan ATC/DDD dan DU 90 di Bagian Bedah Digestif di Salah Satu Rumah Sakit di Bandung. Jurnal Farmasi Klinik Indonesia. 5(4).

Pani S, Barliana MI, Halimah E, Pradipta IS, Annisa N. 2015. Monitoring Penggunaan Antibiotik dengan Metode ATC/DDD dan DU 90%: Studi Observasional di Seluruh Puskesmas Kabupaten Gorontalo Utara. Jurnal Farmasi Klinik Indonesia. 4(4): 275-80.

Perdaka, W., Sagita, D., dan Pratama, S. 2020. Studi Penggunaan Antibiotik Berdasarkan ATC/DDD Dan Du 90% Di Puskesmas X Kota Jambi Periode 2017-2018. Journal of Healthcare Technology and Medicine, 6(1).

Rahayu, L.A.D., Admiyanti, J.C., Khalda, Y.I., Ahda, F.R., Agistany, N.F.F., Setiawati, S., Shofiyanti, N.I., Warnaini. C. 2021. Hipertensi, Diabetes Melitus, dan Obesitas Sebagai Faktor Komorbiditas Utama Terhadap Mortalitas Pasien Covid-19: Sebuah Studi Literatur. Jurnal Ilmiah Mahasiswa Kedokteran Indonesia. 9(1).

Rusdi, M.S. 2021. Mini Review: Farmakologi pada Corona Virus Disease (Covid-19). Jurnal Ilmu Kefarmasian , 2(1) (P-ISSN : 2715-5943; E-ISSN : 2715-5277).

Sultana, J., Cutroneo, P.M., Crisafulli, S., Puglisi, G., Caramori, G., Trifirò, G. 2020. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. Drug Saf. 43(8): 691-698.

WHO. 2021. Guidelines for ATC Classification and DDD Assignment. Oslo : Norwegian Institute of Public Health

Willim, H.A., Infan Ketaren, I., Supit, A.I. 2020. Dampak Coronavirus Disease 2019 terhadap Sistem Kardiovaskular. e-CliniC. 8(2): 237-245

Downloads

Published

2023-03-09

How to Cite

Aseng, C., Wiyono, W., & Jayanti, M. (2023). Evaluasi Penggunaan Antibiotik pada Pasien Covid-19 di RSUP Prof. Dr. R. D. Kandou Manado Periode Januari-Maret 2021. PHARMACON, 12(1), 77–82. https://doi.org/10.35799/pha.12.2023.42200

Issue

Vol. 12 No. 1 (2023): PHARMACON

Section

Articles

License

Copyright (c) 2023 PHARMACON

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)